GlassScriptPhysician profile
Danniell Hicks
NPI 1649847583
$6,294.98
in general payments reported to CMS, 2019-2025
43 companies · $2,555 in 2025
The $2,555 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $819 · 2023: $1,148 · 2024: $1,773 · 2025: $2,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,475.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,536.70 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $791.16 | 2022-2025 | Omnipod |
| Lilly USA, LLC | $575.86 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Mallinckrodt Hospital Products INC. | $329.22 | 2023-2025 | Acthar |
| Xeris Pharmaceuticals, INC. | $319.98 | 2022-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Abbvie INC. | $237.51 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $183.28 | 2022-2025 | |
| Dexcom, INC. | $180.44 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.12 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $162.16 | 2024-2025 | Voquezna |
| Eisai INC. | $161.96 | 2022-2024 | |
| Lundbeck LLC | $133.69 | 2024-2025 | Vyepti |
| Viiv Healthcare Company | $122.00 | 2025 | Cabenuva |
| Bayer Healthcare Pharmaceuticals INC. | $120.50 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $118.45 | 2022-2025 | Breztri, Farxiga, Fasenra |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $110.72 | 2023-2025 | Valtoco |
| Ucb, INC. | $94.48 | 2025 | Rystiggo, Briviact, Fintepla |
| Verona Pharma, INC. | $94.39 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $90.00 | 2025 | Uptravi, Opsumit |
| Amgen INC. | $74.75 | 2022 | |
| Tandem Diabetes Care, INC. | $68.53 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $52.52 | 2024-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $51.80 | 2023-2025 | Strensiq |
| Corcept Therapeutics | $46.64 | 2022-2023 | Korlym |
| Medtronic, INC. | $45.03 | 2024-2025 | Minimed 780g |
| Cequr Corporation | $43.47 | 2023-2024 | Cequr Simplicity |
| Exact Sciences Corporation | $41.74 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $41.65 | 2024-2025 | Gardasil 9, Gardasil, Capvaxive |
| Electromed, INC. | $28.14 | 2022 | |
| Madrigal Pharmaceuticals | $25.09 | 2025 | Rezdiffra |
| Genentech USA, INC. | $24.95 | 2025 | Ocrevus Zunovo |
| Janssen Pharmaceuticals, INC | $22.83 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.47 | 2023 | Quviviq |
| Boston Scientific Corporation | $20.48 | 2025 | General - Dbs |
| Pfizer INC. | $19.85 | 2025 | |
| Sk Life Science, INC. | $19.65 | 2025 | |
| Recordati_rare_diseases_inc. | $19.04 | 2024 | Isturisa, Signifor Lar |
| Baxter Healthcare | $18.85 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Grifols USA, LLC | $18.01 | 2023 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $17.63 | 2025 | Purified Cortrophin Gel |
| Biogen, INC. | $16.18 | 2023 | Tysabri, Vumerity |
| Sequel Med Tech, LLC | $14.70 | 2025 | Twiist |
| Beta Bionics, INC. | $13.36 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danniell Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.